Oramed Pharmaceuticals Files 8-K Report
Ticker: ORMP · Form: 8-K · Filed: Dec 31, 2025 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.012, $0.0001, $0.01, $27,000,000, $13,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, corporate-info
Related Tickers: ORMP
TL;DR
ORMP filed an 8-K on 12/30/25. Standard corporate info, no major news yet.
AI Summary
On December 30, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report. The filing indicates that the company's fiscal year ends on December 31st. No specific business events or financial details were disclosed in the provided excerpt, beyond the standard reporting information.
Why It Matters
This filing confirms Oramed Pharmaceuticals Inc.'s reporting status and provides basic corporate information. Investors can use this to verify company details and filing compliance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no new material information or significant financial events disclosed in the provided text.
Key Numbers
- 001-35813 — SEC File Number (Identifies the company's filing history with the SEC.)
- 98-0376008 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ORAMED PHARMACEUTICALS INC. (company) — Registrant
- December 30, 2025 (date) — Date of earliest event reported
- December 31 (date) — Fiscal year end
- 1185 Avenue of the Americas, Third Floor, New York, New York 10036 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The filing serves as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating the date of the earliest event reported.
When was the earliest event reported in this filing?
The earliest event reported was on December 30, 2025.
What is Oramed Pharmaceuticals Inc.'s fiscal year end?
Oramed Pharmaceuticals Inc.'s fiscal year ends on December 31.
What is the principal executive office address for Oramed Pharmaceuticals Inc.?
The principal executive offices are located at 1185 Avenue of the Americas, Third Floor, New York, New York 10036.
Does this filing disclose any specific business events or financial results?
Based on the provided text, this filing appears to be a standard 8-K report for corporate information and does not disclose specific business events or financial results.
Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2025-12-30 20:51:22
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Tel
- $0.0001 — res of Scilex's common stock, par value $0.0001 per share (the "Scilex Common Stock") a
- $0.01 — Common Stock") at an exercise price of $0.01 per share (the "Subject Warrants") in t
- $27,000,000 — ches for an aggregate purchase price of $27,000,000 (the "Warrant Repurchase"), subject to
- $13,000,000 — tock for an aggregate purchase price of $13,000,000, representing the first tranche of the
- $750,000 — to the Company an initial option fee of $750,000 entitling it to acquire the initial tra
- $14,000,000 — mpany of an aggregate purchase price of $14,000,000 (inclusive of certain prepayments recei
- $28,500,000 — pect of the Warrant Repurchase equal to $28,500,000. SIGNATURES Pursuant to the require
Filing Documents
- ormp-20251230.htm (8-K) — 52KB
- 0001012975-25-000992.txt ( ) — 156KB
- ormp-20251230.xsd (EX-101.SCH) — 25KB
- ormp-20251230_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. (the "Company") entered into an Option Agreement for the Repurchase of Warrants (the "Option Agreement") with Scilex Holding Company ("Scilex") pursuant to which, among other things, the Company granted to Scilex an option to repurchase warrants held by the Company to purchase an aggregate of 6,500,000 shares of Scilex's common stock, par value $0.0001 per share (the "Scilex Common Stock") at an exercise price of $0.01 per share (the "Subject Warrants") in two tranches for an aggregate purchase price of $27,000,000 (the "Warrant Repurchase"), subject to the terms and conditions set forth in the Option Agreement. As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 6, 2025, on September 30, 2025, Scilex repurchased Subject Warrants to purchase 3,130,000 shares of Scilex Common Stock for an aggregate purchase price of $13,000,000, representing the first tranche of the Warrant Repurchase. Prior to such purchase price payment, Scilex delivered to the Company an initial option fee of $750,000 entitling it to acquire the initial tranche of Subject Warrants. On December 30, 2025, Scilex repurchased the remaining Subject Warrants to purchase 3,370,000 shares of Scilex Common Stock upon delivery to the Company of an aggregate purchase price of $14,000,000 (inclusive of certain prepayments received by the Company), in addition to a payment of an option fee of $750,000 entitling it to acquire the second and final tranche of Subject Warrants. Collectively, the Company has received aggregate payments from Scilex in respect of the Warrant Repurchase equal to $28,500,000.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO December 30, 2025